These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 14623357)

  • 1. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.
    van der Stelt M; Di Marzo V
    Eur J Pharmacol; 2003 Nov; 480(1-3):133-50. PubMed ID: 14623357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies.
    El Khoury MA; Gorgievski V; Moutsimilli L; Giros B; Tzavara ET
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):36-50. PubMed ID: 22300746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area.
    Mátyás F; Urbán GM; Watanabe M; Mackie K; Zimmer A; Freund TF; Katona I
    Neuropharmacology; 2008 Jan; 54(1):95-107. PubMed ID: 17655884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of endogenous cannabinoids in cerebral reward mechanisms].
    Wenger T; Fürst S
    Neuropsychopharmacol Hung; 2004 Mar; 6(1):26-9. PubMed ID: 15125311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endocannabinoid system in Parkinson's disease.
    Di Filippo M; Picconi B; Tozzi A; Ghiglieri V; Rossi A; Calabresi P
    Curr Pharm Des; 2008; 14(23):2337-47. PubMed ID: 18781984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice.
    Kortleven C; Fasano C; Thibault D; Lacaille JC; Trudeau LE
    Eur J Neurosci; 2011 May; 33(10):1751-60. PubMed ID: 21410793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocannabinoid system in brain reward processes.
    Solinas M; Goldberg SR; Piomelli D
    Br J Pharmacol; 2008 May; 154(2):369-83. PubMed ID: 18414385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
    Lupica CR; Riegel AC
    Neuropharmacology; 2005 Jun; 48(8):1105-16. PubMed ID: 15878779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.
    Oleson EB; Beckert MV; Morra JT; Lansink CS; Cachope R; Abdullah RA; Loriaux AL; Schetters D; Pattij T; Roitman MF; Lichtman AH; Cheer JF
    Neuron; 2012 Jan; 73(2):360-73. PubMed ID: 22284189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
    Lastres-Becker I; Fezza F; Cebeira M; Bisogno T; Ramos JA; Milone A; Fernández-Ruiz J; Di Marzo V
    Neuroreport; 2001 Jul; 12(10):2125-9. PubMed ID: 11447320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid system as a target for the treatment of motor dysfunction.
    Fernández-Ruiz J
    Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system: physiology and pharmacology.
    Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
    Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.
    Nikolaus S; Antke C; Müller HW
    Behav Brain Res; 2009 Dec; 204(1):32-66. PubMed ID: 19523495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.
    van der Stelt M; Hansen HH; Veldhuis WB; Bär PR; Nicolay K; Veldink GA; Vliegenthart JF; Hansen HS
    Neurotox Res; 2003; 5(3):183-200. PubMed ID: 12835123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid modulation of drug reward and the implications of marijuana legalization.
    Covey DP; Wenzel JM; Cheer JF
    Brain Res; 2015 Dec; 1628(Pt A):233-43. PubMed ID: 25463025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An endocannabinoid hypothesis of drug reward and drug addiction.
    Onaivi ES
    Ann N Y Acad Sci; 2008 Oct; 1139():412-21. PubMed ID: 18991888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid control of motor function at the basal ganglia.
    Fernández-Ruiz J; Gonzáles S
    Handb Exp Pharmacol; 2005; (168):479-507. PubMed ID: 16596785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity.
    Patel S; Rademacher DJ; Hillard CJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):880-8. PubMed ID: 12808005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.